KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Moderna (MRNA) EBITDA (2017 - 2025)

Moderna (MRNA) has disclosed EBITDA for 9 consecutive years, with -$857.0 million as the latest value for Q4 2025.

  • On a quarterly basis, EBITDA rose 31.22% to -$857.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$3.1 billion, a 22.08% increase, with the full-year FY2025 number at -$3.1 billion, up 22.08% from a year prior.
  • EBITDA was -$857.0 million for Q4 2025 at Moderna, down from -$260.0 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $5.4 billion in Q4 2021 to a low of -$2.0 billion in Q3 2023.
  • A 5-year average of $572.9 million and a median of -$165.0 million in 2024 define the central range for EBITDA.
  • Peak YoY movement for EBITDA: soared 2609.84% in 2021, then crashed 20866.67% in 2024.
  • Moderna's EBITDA stood at $5.4 billion in 2021, then tumbled by 70.79% to $1.6 billion in 2022, then plummeted by 99.62% to $6.0 million in 2023, then plummeted by 20866.67% to -$1.2 billion in 2024, then surged by 31.22% to -$857.0 million in 2025.
  • Per Business Quant, the three most recent readings for MRNA's EBITDA are -$857.0 million (Q4 2025), -$260.0 million (Q3 2025), and -$907.0 million (Q2 2025).